Investor
Affinity Asset Advisors, LLC
CIK 0001773195 · filed 2026-05-14 · SEC filing
13F book
$1.94B
Positions
95
20 new · 11 sold
Largest name
5.6%
Apogee Therapeutics, Inc. · APGE
Est. mark
$116.3M
Price effect on 75 names still held. Flow $197.1M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. | APGE | 1.28M | $108.2M | 5.6% | $10.7M | Added$14.9M |
| Xenon Pharmaceuticals Inc. | XENE | 1.68M | $97.4M | 5.0% | $16.7M | Added$41.4M |
| Erasca, Inc. | ERAS | 5.35M | $86.6M | 4.5% | $48.6M | Added$72.1M |
| Insmed Inc | INSM | 480K | $78.5M | 4.1% | −$4.73M | Added$171.6K |
| Roivant Sciences Ltd. | ROIV | 2.8M | $77.6M | 4.0% | $10.2M | Added$40.7M |
| Spyre Therapeutics, Inc. | SYRE | 1.28M | $64.5M | 3.3% | $22.6M | Cut$17.6M |
| Centessa Pharmaceuticals Plc | — | 1.4M | $55.6M | 2.9% | $8.83M | Added$40.6M |
| Praxis Precision Medicines I | — | 170K | $54.8M | 2.8% | $4.67M | Cut$245.4K |
| Anaptysbio, Inc | ANAB | 940K | $52.1M | 2.7% | $3.1M | Added$30.6M |
| Alkermes plc. | ALKS | 1.35M | $47.7M | 2.5% | $7.38M | Added$19.8M |
| Cytokinetics Inc | CYTK | 700.5K | $46.2M | 2.4% | $1.66M | Cut−$4.66M |
| Abivax Sa | — | 405K | $45.1M | 2.3% | −$9.52M | Cut−$23M |
| Teva Pharmaceutical Inds Ltd | — | 1.4M | $42.2M | 2.2% | −$1.53M | Held |
| Arcellx Inc | — | 362.8K | $41.7M | 2.2% | $18M | Cut$7.51M |
| Nuvalent Inc | — | 300K | $30.7M | 1.6% | $558K | Cut−$1.72M |
| Terns Pharmaceuticals Inc | — | 562.6K | $29.7M | 1.5% | $6.78M | Added$7.44M |
| Dianthus Therapeutics Inc | — | 350K | $29.4M | 1.5% | $4.91M | Added$24.6M |
| Lexeo Therapeutics, Inc. | LXEO | 5.05M | $29M | 1.5% | −$13.4M | Added−$2.79M |
| Cogent Biosciences, Inc. | COGT | 750K | $28.9M | 1.5% | $1.04M | Added$16.4M |
| Madrigal Pharmaceuticals, Inc. | MDGL | 55K | $28.8M | 1.5% | −$1.83M | Added$10.7M |
| Sutro Biopharma, Inc. | STRO | 1.07M | $26.6M | 1.4% | $9.98M | Added$18M |
| Forte Biosciences, Inc. | FBRX | 1.01M | $26.2M | 1.4% | −$1.36M | Added−$775.4K |
| Oruka Therapeutics, Inc. | ORKA | 499.7K | $24.5M | 1.3% | $9.36M | Cut$190K |
| Trevi Therapeutics, Inc. | TRVI | 2M | $23.9M | 1.2% | −$1.18M | Cut−$3.06M |
| Ovid Therapeutics Inc. | OVID | 10.6M | $23.6M | 1.2% | $4.22M | Added$12M |
| Enliven Therapeutics, Inc. | ELVN | 586.9K | $23M | 1.2% | — | New |
| Ascendis Pharma A/S | ASND | 95K | $21.7M | 1.1% | $464.7K | Added$15.3M |
| Mineralys Therapeutics, Inc. | MLYS | 750K | $20.3M | 1.0% | −$6.72M | Added−$6.17M |
| Avalo Therapeutics, Inc. | AVTX | 1.34M | $20M | 1.0% | −$3.39M | Added$931.6K |
| Protagonist Therapeutics, Inc | PTGX | 172.1K | $18.1M | 0.9% | $3.11M | Held |
| Celldex Therapeutics Inc New | — | 500K | $15.9M | 0.8% | $1.6M | Added$6.35M |
| Zura Bio Ltd | ZURA | 2.56M | $15.3M | 0.8% | $1.29M | Added$5.75M |
| Nurix Therapeutics, Inc. | NRIX | 967.6K | $15M | 0.8% | −$3.36M | Held |
| Savara Inc | SVRA | 2.51M | $13.7M | 0.7% | −$1.43M | Cut−$3.15M |
| Omeros Corp | OMER | 6.53M | $13.2M | 0.7% | −$6.16M | Held |
| Perspective Therapeutics, Inc. | CATX | 3.16M | $13.2M | 0.7% | $426K | Added$12.4M |
| Helix Acquisition Corp. III | HLXC | 1.25M | $12.7M | 0.7% | — | New |
| Arrowhead Pharmaceuticals In | — | 200K | $12.5M | 0.6% | −$258.3K | Added$7.89M |
| Galecto Inc | DMRA | 450K | $11.7M | 0.6% | — | New |
| Eupraxia Pharmaceuticals Inc. | EPRX | 1.59M | $11.5M | 0.6% | −$93K | Added$9.24M |
| Alto Neuroscience, Inc. | ANRO | 500K | $11.2M | 0.6% | — | New |
| BridgeBio Pharma, Inc. | BBIO | 150K | $11.1M | 0.6% | −$334.5K | Cut−$13.3M |
| Cullinan Therapeutics, Inc. | CGEM | 781.3K | $11.1M | 0.6% | $3.02M | Cut−$8.9M |
| Belite Bio, Inc | BLTE | 65K | $10.4M | 0.5% | −$10.4K | Added$7.16M |
| Wave Life Sciences Ltd. | WVE | 1.4M | $10.2M | 0.5% | −$13.7M | Cut−$35.7M |
| Vera Therapeutics, Inc. | VERA | 250K | $10.1M | 0.5% | −$2.6M | Held |
| Tyra Biosciences, Inc. | TYRA | 257.5K | $9.86M | 0.5% | — | New |
| Revolution Medicines Inc | — | 100K | $9.72M | 0.5% | $1.76M | Held |
| Jade Biosciences, Inc. | JBIO | 640K | $8.99M | 0.5% | −$883.1K | Cut−$2.04M |
| Travere Therapeutics, Inc. | TVTX | 300K | $8.91M | 0.5% | −$2.55M | Held |
| Newamsterdam Pharma Company | — | 275K | $8.8M | 0.5% | −$844.3K | Held |
| Cogent Biosciences, Inc. | COGT | 7M | $8.59M | 0.4% | $50.7K | Added$7.41M |
| Korro Bio, Inc. | KRRO | 706.9K | $8M | 0.4% | — | New |
| Celcuity Inc. | CELC | 3M | $7.31M | 0.4% | $798.3K | Held |
| Crispr Therapeutics Ag | CRSP | 150K | $7.14M | 0.4% | — | New |
| SpyGlass Pharma, Inc. | SGP | 250K | $6.48M | 0.3% | — | New |
| Compass Pathways Plc | CMPS | 1.11M | $6.13M | 0.3% | −$274K | Added$4.75M |
| iBio, Inc. | IBIO | 3.11M | $5.9M | 0.3% | −$61.7K | Added$1.93M |
| Establishment Labs Hldgs Inc | — | 100K | $5.68M | 0.3% | −$1.61M | Cut−$8.9M |
| Anteris Technologies Global Corp. | AVR | 912.4K | $5.06M | 0.3% | $272.5K | Added$2.64M |
| Newamsterdam Pharma Company | — | 245K | $4.91M | 0.3% | −$725.2K | Held |
| Viridian Therapeutics Inc | — | 250K | $4.89M | 0.3% | −$2.89M | Held |
| Climb Bio, Inc. | CLYM | 700K | $4.79M | 0.2% | $1.99M | Cut−$405K |
| Rezolute, Inc. | RZLT | 1.55M | $4.72M | 0.2% | $1.07M | Cut−$828.4K |
| Sagimet Biosciences Inc. | SGMT | 868K | $4.54M | 0.2% | −$603.3K | Cut−$2.26M |
| MBX Biosciences, Inc. | MBX | 150K | $4.48M | 0.2% | −$253.5K | Cut−$3.41M |
| Taysha Gene Therapies, Inc. | TSHA | 1M | $4.47M | 0.2% | −$1.03M | Cut−$13.7M |
| Veradermics, Inc | MANE | 70K | $4.42M | 0.2% | — | New |
| Generate Biomedicines, Inc. | GENB | 350K | $4.38M | 0.2% | — | New |
| Engene Holdings Inc | — | 610.4K | $4.16M | 0.2% | −$1.36M | Cut−$1.65M |
| ArriVent BioPharma, Inc. | AVBP | 175K | $4.04M | 0.2% | $442.5K | Added$1.02M |
| Relay Therapeutics, Inc. | RLAY | 400K | $3.98M | 0.2% | — | New |
| Proqr Thrapeutics N V | — | 2.45M | $3.98M | 0.2% | −$981.7K | Held |
| Verrica Pharmaceuticals Inc. | VRCA | 707.3K | $3.74M | 0.2% | −$2.14M | Held |
| Precision Biosciences Inc | DTIL | 597.9K | $3.29M | 0.2% | — | New |
| Karyopharm Therapeutics Inc. | KPTI | 500K | $2.79M | 0.1% | −$895K | Cut−$3.76M |
| Sol-Gel Technologies Ltd. | SLGL | 35K | $2.77M | 0.1% | — | New |
| Crinetics Pharmaceuticals In | — | 75K | $2.72M | 0.1% | −$767.2K | Held |
| Oaktree Acquisition Corp Iii | — | 250K | $2.66M | 0.1% | $10K | Held |
| NextCure, Inc. | NXTC | 241.8K | $2.58M | 0.1% | −$848.8K | Cut−$926.4K |
| Immunovant, Inc. | IMVT | 100K | $2.48M | 0.1% | −$58K | Cut−$2.6M |
| Equillium, Inc. | EQ | 1.23M | $2.45M | 0.1% | — | New |
| Sab Biotherapeutics Inc | — | 575K | $2.2M | 0.1% | — | New |
| Corcept Therapeutics Inc | CORT | 50K | $2.02M | 0.1% | — | New |
| Orchestra Biomed Hldgs Inc | — | 402.6K | $1.71M | 0.1% | $40.3K | Cut−$666.3K |
| Kezar Life Sciences Inc | — | 229.1K | $1.7M | 0.1% | $258.9K | Held |
| Macrogenics Inc | MGNX | 500K | $1.45M | 0.1% | $619.9K | Added$665.3K |
| Adlai Nortye Ltd. | ANL | 164.7K | $1.14M | 0.1% | — | New |
| Alector, Inc. | ALEC | 500K | $1.07M | 0.1% | — | New |
| OnKure Therapeutics, Inc. | OKUR | 241K | $997.6K | 0.1% | — | New |
| LENZ Therapeutics, Inc. | LENZ | 100K | $915K | 0.0% | — | New |
| X4 Pharmaceuticals, Inc | XFOR | 145K | $598.9K | 0.0% | $18.8K | Held |
| Q32 Bio Inc. | QTTB | 27.8K | $178.3K | 0.0% | $86.1K | Held |
| Adagio Med Hldgs Inc | — | 80K | $92K | 0.0% | $8.8K | Held |
| Rocket Pharmaceuticals Inc | — | 75K | $1.18K | 0.0% | −$645 | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.